Prophylactic potential of montelukast against mild colitis induced by dextran sulphate sodium in rats

Journal of Physiology and Pharmacology

Volumn 58, Issue 3, 2007, Pages 455-467

  Holma, R ^a,b   Salmenpera P ^a   Virtanen, I ^a   Vapaatalo, Heikki ^a   Korpela, R ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FOUNDATION FOR NUTRITION RESEARCH   (Finland)

Author keywords

Cys LT 1 receptor; Cysteinyl leukotrienes; Dextran sulphate sodium (DSS) induced colitis; Leukotriene B4; Montelukast; Prostaglandin E 2

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DEXTRAN SULFATE; LEUKOTRIENE B4; LEUKOTRIENE E4; MONTELUKAST; NITRIC OXIDE SYNTHASE; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN E2; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOODY DIARRHEA; COLITIS; COLON; CONTROLLED STUDY; FECES ANALYSIS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MONOCYTE; NONHUMAN; OCCULT BLOOD; PROPHYLAXIS; RAT; WEIGHT REDUCTION; WESTERN BLOTTING;

ACETATES; ADMINISTRATION, ORAL; ANIMALS; BICYCLO COMPOUNDS; BLOTTING, WESTERN; BODY WEIGHT; COLITIS; COLON; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DEXTRAN SULFATE; DINOPROSTONE; IMMUNOCHEMISTRY; IMMUNOGLOBULIN G; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE B4; MALE; NITRIC OXIDE SYNTHASE TYPE II; OCCULT BLOOD; QUINOLINES; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX; THROMBOXANE B2;

EID: 34948904872     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Jörg A, Henderson WR, Murphy RC, Klebanoff SJ. Leukotriene generation by eosinophils. J Exp Med 1982; 155: 390-402.
2. MacGlashan DW, Schleimer RP, Peters SP, et al. Generation of leukotrienes by purified human lung mast cells. J Clin Invest 1982; 70: 747-751.
3. 4 synthesized by human alveolar macrophages. Biochem Biophys Res Commun 1983; 111: 518-524.
4. Williams JD, Czop JK, Austen KF. Release of leukotrienes by human monocytes on stimulation of their phagocytic receptor for particulate activators. J Immunol 1984; 132: 3034-3040.
5. Lewis RA, Austen KF. The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest 1984; 73: 889-897.
6. Drazen JM, Austen KF, Lewis RA, et al. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci USA 1980; 77: 4354-4358.
7. 4. Acta Physiol Scand 1980; 110: 331-333.
8. Spada CS, Woodward DF, Hawley SB, Nieves AL. Leukotrienes cause eosinophil emigration into conjunctival tissue. Prostaglandins 1986; 31: 795-809.
9. Dahlén SE. Leukotriene receptors and their antagonists. In SRS-A to leukotrienes. The dawning of a new treatment, S Holgate, SE Dahlén (eds). London, Blackwell Science, 1997, pp. 155-166.
10. Jett MF, Marshall P, Fondacaro JD, Smith PL. Action of peptidoleukotrienes on ion transport in rabbit distal colon in vitro. J Pharmacol Exp Ther 1991; 257: 698-705.
11. Goldenberg MM, Subers EM. The reactivity of rat isolated gastrointestinal tissues to leukotrienes. Eur J Pharmacol 1982; 78: 463-466.
12. 2 on human, porcine and guinea pig lung parenchyma. Agents Actions 1984; 14: 88-92.
13. Peskar BM, Dreyling KW, Peskar BA, May B, Goebell H. Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid. Agents Actions 1986; 18: 381-383.
14. Peskar BM, Dreyling KW, May B, Schaarschmidt K, Goebell H. Possible mode of action of 5-aminosalicylic acid. Dig Dis Sci 1987; 32: 51S-56S.
15. Wardle TD, Hall L, Turnberg LA. Inter-relationships between inflammatory mediators released from colonic mucosa in ulcerative colitis and their effects on colonic secretion. Gut 1993; 34: 503-508.
16. 4 release by unaffected jejunal mucosa in patients with inactive Crohn's disease. Gut 1994; 35: 517-522.
17. Eberhart CE, Dubois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology 1995; 109: 285-301.
18. 4 in rabbit colitis. Relationship to inflammation. Gastroenterology 1987; 92: 33-39.
19. Eliakim R, Karmeli F, Okon E, Rachmilewitz D. Ketotifen effectively prevents mucosal damage in experimental colitis. Gut 1992; 33: 1498-1503.
20. Yuceyar H, Ozutemiz O, Huseyinov A, et al. Is administration of n-3 fatty acids by mucosal enema protective against trinitrobenzene-induced colitis in rats? Prostaglandins Leukot Essent Fatty Acids 1999; 61: 339-345.
21. Karmeli F, Eliakim R, Okon E, Samuni A, Rachmilewitz D. A stable nitroxide radical effectively decreases mucosal damage in experimental colitis. Gut 1995; 37: 386-393.
22. Rachmilewitz D, Karmeli F, Okon E. Sulfhydryl blocker-induced rat colonic inflammation is ameliorated by inhibition of nitric oxide synthase. Gastroenterology 1995; 109: 98-106.
23. Oketani K, Inoue T, Murakami M. Effect of E3040, an inhibitor of 5-lipoxygenase and thromboxane synthase, on rat bowel damage induced by lipopolysaccharide. Eur J Pharmacol 2001; 427: 159-166.
24. Zipser RD, Patterson JB, LeDuc LE. Chemotactic peptide stimulation of leukotrienes from healthy and inflamed rabbit colons. J Pharmacol Exp Ther 1987; 241: 218-222.
25. Hammerbeck DM, Brown DR. Presence of immunocytes and sulfidopeptide leukotrienes in the inflamed guinea pig distal colon. Inflammation 1996; 20: 413-425.
26. 2 before and after induction of colitis with trinitrobenzenesulfonic acid in rats decreases inflammation. Gastroenterology 1989; 96: 1290-1300.
27. 4 participates in colonic transit disturbances induced by intracolonic administration of trinitrobenzene sulfonic acid in rats. Gastroenterology 1992; 102: 149-156.
28. 4 antagonist on colonic damage induced by intracolonic administration of trinitrobenzene sulfonic acid in rats. J Gastroenterol 1995; 30: 34-40.
29. Mahgoub AA, El-Medany AA, Hager HH, Mustafa AA, El-Sabah DM. Evaluating the prophylactic potential of zafirlukast against the toxic effects of acetic acid on the rat colon. Toxicol Lett 2003; 145: 79-87.
30. Holma R, Salmenperä P, Riutta A, Virtanen I, Korpela R, Vapaatalo H. Acute effects of the cysleukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats. Eur J Pharmacol 2001; 429: 309-318.
31. Bylund-Fellenius AC, Landström E, Axelsson LG, Midtvedt T. Experimental colitis induced by dextran sulphate in normal and germfree mice. Microbial Ecol Health Dis 1994; 7: 207-215.
32. Axelsson LG, Landström E, Bylund-Fellenius AC. Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. Aliment Pharmacol Ther 1998; 12: 925-934.
33. 4 receptor antagonist. Can J Physiol Pharmacol 1995; 73: 191-201.
34. Hele DJ, Birrell MA, Webber SE, Foster ML, Belvisi MG. Mediator involvement in antigen-induced bronchospasm and microvascular leakage in the airways of ovalbumin sensitized Brown Norway rats. Br J Pharmacol 2001; 132: 481-488.
35. Cooper HS, Murthy SNS, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69: 238-249.
36. Pfeiffer CJ, Qiu BS. Effects of chronic nitric oxide synthase inhibition on TNB-induced colitis in rats. J Pharm Pharmacol 1995; 47: 827-832.
37. Samuelsson B, Dahlén SE, Lindgren JÅ, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 1987; 237: 1171-1176.
38. Whittle BJR, Vane JR. Prostanoids as regulators of gastrointestinal function. In Physiology of the gastrointestinal tract, LR Johnson (ed). New York, Raven Press, 1987, pp. 143-180.
39. Wallace JL, Whittle BJR, Boughton-Smith NK. Prostaglandin protection of rat colonic mucosa from damage induced by ethanol. Dig Dis Sci 1985; 30: 866-876.
40. Fedorak RN, Empey LR, MacArthur C, Jewell LD. Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. Gastroenterology 1990; 98: 615-625.
41. 2 inhibits lesion formation in dextran sodium sulphate-induced colitis in rats and reduces the levels of mucosal inflammatory cytokines. Scand J Immunol 2000; 51: 23-28.
42. 2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat. Br J Pharmacol 2003; 138: 678-688.
43. Villegas I, Alarcón de la Lastra C, Orjales A, La Casa C. A new flavonoid derivative, dosmalfate, attenuates the development of dextran sulphate sodium-induced colitis in mice. Int Immunopharmacol 2003; 3: 1731-1741.
44. Martin AR, Villegas I, Alarcón de la Lastra C. The COX-2 inhibitor, rofecoxib, ameliorates detran sulphate sodium induced colitis in mice. Inflamm Res 2005; 54: 145-151.
45. Singh VP, Patil CS, Jain NK, Kulkarni SK. Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats. Pharmacol 2004; 72: 77-84.
46. 2 in protection against mucosal damage. Digestion 2001; 63 Suppl 1: 73-80.
47. Morteau O, Morham SG, Sellon R, et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest 2000; 105: 469-478.
48. Tessner TG, Cohn SM, Schloemann S, Stenson WF. Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice. Gastroenterology 1998; 115: 874-882.
49. Luceri C, Guglielmi F, Lodovici M, Giannini L, Messerini L, Dolara P. Plant phenolic 4-coumaric acid protects against intestinal inflammation in rats. Scand J Gastroenterol 2004; 39: 1128-1133.
50. Kubes P. Inducible nitric oxide synthase: a little bit of good in all of us. Gut 2000; 47: 6-9.
51. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 2003; 54: 469-487.
52. Perner A, Rask-Madsen J. Review article: the potential role of nitric oxide in chronic inflammatory bowel disorders. Aliment Pharmacol Ther 1999; 13: 135-144.
53. Kankuri E, Vaali K, Knowles RG, et al. Suppression of acute experimental colitis by a highly selective inducible nitric-oxide synthase inhibitor, N-[3-(aminomethyl)benzyl]acetamidine. J Pharmacol Exp Ther 2001; 298: 1128-1132.
54. Rumi G, Tsuboughi R, Nishio H, Kato S, Mozsik G, Takeuchi K. Dual role of endogenous nitric oxide in development of dextran sulphate sodium-induced colitis in rats. J Physiol Pharmacol 2004; 55: 823-836.